Randomized Controlled Trial of Remimazolam Compared with Placebo in Japanese Patients Undergoing Colonoscopy: A Phase III, Investigator-Initiated Trial
Authors:
- Ryoji IchijimaRIRyoji Ichijima
- Hisatomo IkeharaHIHisatomo Ikehara
- Hiroyuki OnoHOHiroyuki Ono
- Kinichi HottaKHKinichi Hotta
- Daisuke YamaguchiDYDaisuke Yamaguchi
- Mitsuru EsakiMEMitsuru Esaki
- Yosuke MinodaYMYosuke Minoda
- Yasuhiko NagataYNYasuhiko Nagata
- Kanako OguraKOKanako Ogura
- Shinsuke KiriyamaSKShinsuke Kiriyama
- Tetsuya SumiyoshiTSTetsuya Sumiyoshi
- Yuichi KanmuraYKYuichi Kanmura
Open Access
- 26 July 2024
- journal article
- research article
- Published by S. Karger AG in Digestion
- Vol. 105 (6) , 448-456
Abstract
Introduction: We conducted an investigator-initiated clinical trial in which remimazolam was used to achieve sedation in patients undergoing colonoscopies. Methods: This multicenter, double-blind, placebo-controlled, phase III investigator-initiated trial included patients who underwent colonoscopy under sedation with remimazolam (initial dose: 3 mg; additional dose: 1 mg) or normal saline (placebo). The primary endpoint of the study was the successful sedation rate during colonoscopy, defined as achieving a Modified Observer’s Assessment of Alertness/Sedation (MOAA/S) score of ≤4 before the procedure, maintaining this score throughout colonoscopy, and requiring no more than five additional drug doses per 15 min. Results: The sedation success rate was 95.0% (38/40 patients) in the remimazolam group and 0.0% (0/11 patients) in the placebo group (p < 0.01). The time from the end of procedure to regaining consciousness was 0.0 (interquartile range: 0.0–0.0) min in both groups. The time from the end of the procedure to ambulation was 5.0 (interquartile range: 0.0–10.0) min in the remimazolam group and 0.0 (interquartile range: 0.0–0.0) min in the placebo group (p = 0.02). Serious adverse events were not observed. Conclusion: The use of remimazolam to achieve sedation in Japanese patients undergoing colonoscopy was more effective than placebo.Keywords
This publication has 20 references indexed in Scilit:
- Efficacy and safety of remimazolam in procedural sedation and analgesiaMedicine, 2020
- Efficacy and safety of remimazolam versus propofol for general anesthesia: a multicenter, single-blind, randomized, parallel-group, phase IIb/III trialJournal of Anesthesia, 2020
- A phase III study evaluating the efficacy and safety of remimazolam (CNS 7056) compared with placebo and midazolam in patients undergoing colonoscopyGastrointestinal Endoscopy, 2018
- A phase IIb study comparing the safety and efficacy of remimazolam and midazolam in patients undergoing colonoscopyGastrointestinal Endoscopy, 2016
- A Phase IIa, Randomized, Double-Blind Study of Remimazolam (CNS 7056) Versus Midazolam for Sedation in Upper Gastrointestinal EndoscopyAnesthesia & Analgesia, 2015
- A Phase Ib, Dose-Finding Study of Multiple Doses of Remimazolam (CNS 7056) in Volunteers Undergoing ColonoscopyAnesthesia & Analgesia, 2013
- Sedation in Screening Colonoscopy: Impact on Quality Indicators And ComplicationsAmerican Journal of Gastroenterology, 2012
- Remimazolam, a short-acting GABA(A) receptor agonist for intravenous sedation and/or anesthesia in day-case surgical and non-surgical procedures.2010
- Prevention of Colorectal Cancer by Colonoscopic PolypectomyNew England Journal of Medicine, 1993
- VALIDITY AND RELIABILITY OF THE OBSERVERS ASSESSMENT OF ALERTNESS SEDATION SCALE - STUDY WITH INTRAVENOUS MIDAZOLAM1990